X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-08-02 | NVCR | Cordova Ashley | CFO | S - Sale | $20.14 | -688 | 219,179 | 0% | -$13,857 | ||||||
| D | 2024-06-04 | NVCR | Vernon W Anthony | Dir | S - Sale+OE | $23.89 | -964 | 334,683 | 0% | -$23,033 | |||||
| D | 2024-06-04 | NVCR | Scannell Timothy J | Dir | S - Sale+OE | $23.89 | -964 | 10,945 | -8% | -$23,027 | |||||
| D | 2024-06-04 | NVCR | Leung Gabriel | Dir | S - Sale+OE | $23.89 | -964 | 161,367 | -1% | -$23,025 | |||||
| M | 2024-03-01 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $16.02 | -3,324 | 251,235 | -1% | -$53,253 | |||||
| M | 2024-03-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.02 | -2,519 | 160,098 | -2% | -$40,358 | |||||
| D | 2024-02-28 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale+OE | $16.14 | -2,078 | 162,617 | -1% | -$33,545 | |||||
| D | 2024-02-28 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale+OE | $16.14 | -2,303 | 254,559 | -1% | -$37,177 | |||||
2023-11-07 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $12.65 | -382 | 124,511 | 0% | -$4,832 | ||||||
2023-09-01 | NVCR | Cordova Ashley | CFO | S - Sale | $21.82 | -883 | 99,650 | -1% | -$19,265 | ||||||
2023-09-01 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $21.82 | -294 | 209,825 | 0% | -$6,414 | ||||||
2023-09-01 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $21.82 | -273 | 124,893 | 0% | -$5,956 | ||||||
2023-08-02 | NVCR | Cordova Ashley | CFO | S - Sale | $30.25 | -1,144 | 100,533 | -1% | -$34,607 | ||||||
| M | 2023-03-03 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.55 | -13,609 | 54,284 | -20% | -$1,028,165 | |||||
2023-03-03 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $76.16 | -21,421 | 124,799 | -15% | -$1,631,411 | ||||||
2023-03-03 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $76.16 | -25,635 | 209,753 | -11% | -$1,952,346 | ||||||
2023-03-03 | NVCR | Cordova Ashley | CFO | S - Sale | $76.16 | -5,505 | 101,310 | -5% | -$419,257 | ||||||
2023-03-03 | NVCR | Burke William Patrick | CHRO | S - Sale | $76.16 | -593 | 66,090 | -1% | -$45,163 | ||||||
2023-03-02 | NVCR | Burke William Patrick | CHRO | S - Sale | $75.28 | -281 | 66,683 | 0% | -$21,153 | ||||||
2023-03-02 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale | $75.28 | -937 | 146,220 | -1% | -$70,535 | ||||||
2023-03-02 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale | $75.28 | -1,213 | 235,388 | -1% | -$91,312 | ||||||
2023-03-02 | NVCR | Cordova Ashley | CFO | S - Sale | $75.28 | -1,055 | 106,815 | -1% | -$79,418 | ||||||
| M | 2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.95 | -2,903 | 67,893 | -4% | -$223,393 | |||||
2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.38 | -4,107 | 58,988 | -7% | -$309,578 | ||||||
| D | 2023-03-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $76.36 | -1,684 | 63,095 | -3% | -$128,594 | |||||
| D | 2023-03-01 | NVCR | Shah Pritesh | Chief Growth Officer | S - Sale+OE | $76.36 | -1,923 | 99,975 | -2% | -$146,845 | |||||
| D | 2023-03-01 | NVCR | Cordova Ashley | CFO | S - Sale+OE | $76.36 | -2,198 | 96,062 | -2% | -$167,845 | |||||
| D | 2023-03-01 | NVCR | Burke William Patrick | CHRO | S - Sale+OE | $76.36 | -755 | 66,964 | -1% | -$57,654 | |||||
| D | 2023-03-01 | NVCR | Groenhuysen Wilhelmus Cm | COO | S - Sale+OE | $76.36 | -2,164 | 184,615 | -1% | -$165,248 | |||||
| D | 2023-01-05 | NVCR | Weinberg Uri | Chief Science Officer | S - Sale+OE | $116.14 | -8,143 | 43,286 | -16% | -$945,756 | |||||
| D | 2023-01-05 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $112.25 | -39,507 | 46,158 | -46% | -$4,434,654 | |||||
2023-01-05 | NVCR | Shah Pritesh | Chief Commercial Officer | S - Sale | $108.00 | -387 | 82,843 | 0% | -$41,796 | ||||||
| D | 2023-01-05 | NVCR | Danziger Asaf | CEO | S - Sale+OE | $108.74 | -212,500 | 13,622 | -94% | -$23,106,230 | |||||
2022-10-13 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.01 | -6,754 | 43,626 | -13% | -$513,372 | ||||||
2022-10-06 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $84.37 | -6,754 | 50,380 | -12% | -$569,835 | ||||||
2022-09-29 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.35 | -6,754 | 57,134 | -11% | -$522,422 | ||||||
2022-09-22 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.00 | -6,754 | 63,888 | -10% | -$520,058 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |